CLINICAL TRIALS PROFILE FOR TELMISARTAN AND AMLODIPINE

All Clinical Trials for Telmisartan And Amlodipine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00240474 ↗	A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)	Completed	Boehringer Ingelheim	Phase 4	2002-12-01	The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with predominantly systolic hypertension.
NCT00242814 ↗	Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities	Completed	Boehringer Ingelheim	Phase 4	2005-10-01	The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome. Moreover, this study will compare serum level of inflammatory markers of the metabolic syndrome after 6 weeks of treatment. An ancillary study performed in one center will assess adipocyte differentiation (PPAR gamma stimulation) in 30 subjects (15 per arm).
NCT00281580 ↗	Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension	Completed	Boehringer Ingelheim	Phase 3	2006-04-01	To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
NCT00509470 ↗	Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine	Completed	Tokyo University	Phase 4	2007-07-01	The purpose of this study is to compare depressor effect and safety between combination therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive patients.
NCT00538486 ↗	A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients	Completed	Third Military Medical University	Phase 4	2008-02-01	The epidemic of obesity is associated with a considerable rise in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and hypertension. Insulin resistance plays an important role in the pathogenesis of obesity related hypertension. These patients are at high risk to suffer from cardiovascular events. However, current guidelines for treatment of hypertension do not provide specific recommendation for the pharmacotherapy of obese hypertensive patients due to lack of prospective randomized intervention studies in non-diabetic obese hypertensive patients. Aside from their antihypertensive effects, angiotensin II receptor blockers (ARB) were shown to improve insulin sensitivity. Furthermore, metformin is commonly used to treat the obese type 2 diabetes mellitus. Metformin can also lower body weight and increase insulin sensitivity. In a prospective, double-blind, double-dummy, randomized, parallel-group study, we will evaluate the effects of ARB (telmisartan and candesartan) or amlodipine combination with metformin on weight gain, visceral fat, and metabolic parameters in obese hypertensive patients without diabetes mellitus compared with obese hypertensives on ARB or amlodipine treatment alone. This study will help to develop future comprehensive treatment strategies and guidelines for obesity related hypertension.
NCT00550953 ↗	Filtered Trial for Telmisartan 40mg Non-responder	Completed	Boehringer Ingelheim	Phase 3	2007-10-01	The primary purpose of this study is to: Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy.
NCT00553267 ↗	Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension	Completed	Boehringer Ingelheim	Phase 3	2007-11-01	The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in reducing blood pressure at eight weeks compared with amlodipine 10mg monotherapy (A10) in patients who fail to respond to six weeks treatment with A10.

Clinical Trial Conditions for Telmisartan And Amlodipine

Condition Name

Condition Name for Telmisartan And Amlodipine
Intervention	Trials
Hypertension	57
Healthy	16
Essential Hypertension	7
Hyperlipidemia	7

Condition MeSH

Condition MeSH for Telmisartan And Amlodipine
Intervention	Trials
Hypertension	57
Hyperlipidemias	9
Essential Hypertension	7
Dyslipidemias	5

Clinical Trial Locations for Telmisartan And Amlodipine

Trials by Country

Trials by Country for Telmisartan And Amlodipine
Location	Trials
Korea, Republic of	70
United States	57
Japan	12
Canada	9
China	8

Trials by US State

Trials by US State for Telmisartan And Amlodipine
Location	Trials
Florida	5
Pennsylvania	3
Oklahoma	3
Georgia	3
California	3

Clinical Trial Progress for Telmisartan And Amlodipine

Clinical Trial Phase

Clinical Trial Phase for Telmisartan And Amlodipine
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	30
Phase 2	2

Clinical Trial Status

Clinical Trial Status for Telmisartan And Amlodipine
Clinical Trial Phase	Trials
Completed	76
Unknown status	9
Recruiting	4

Clinical Trial Sponsors for Telmisartan And Amlodipine

Sponsor Name

Sponsor Name for Telmisartan And Amlodipine
Sponsor	Trials
Boehringer Ingelheim	36
Chong Kun Dang Pharmaceutical	17
Yuhan Corporation	7

Sponsor Type

Sponsor Type for Telmisartan And Amlodipine
Sponsor	Trials
Industry	77
Other	23